Ananth Sridhar

Ananth Sridhar is a seasoned executive with extensive experience in corporate development and operations within the biotechnology sector. Currently serving as Chief Operating Officer and Senior Vice President of Corporate Development at BridgeBio's Eidos Therapeutics and Calcilytix Therapeutics since August 2018, Ananth has held various leadership roles in the company, including Vice President and Senior Director. Prior experience includes advisory roles at VALIS Genomics and Nanoly Bioscience, as well as significant positions at Regeneron Pharmaceuticals, where Ananth contributed to new product planning and participated in an Executive Leadership Program. Ananth's career began with analytical roles, including positions at Health Advances, Stanford University School of Medicine, and Genentech. Ananth holds a B.S. with Honors in Chemical Engineering from Stanford University and an MBA from Harvard Business School.